Exploring the Role of the TL1A-DR3 Pathway in Hidradenitis Suppurativa - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exploring the Role of the TL1A-DR3 Pathway in Hidradenitis Suppurativa

  • By

  • Juling Sia

  • Bernett Lee

  • Hazel H. Oon

  • April 22, 2026

Share

Clinical Scorecard: Exploring the Role of the TL1A-DR3 Pathway in Hidradenitis Suppurativa

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationIndividuals with moderate-to-severe Hidradenitis Suppurativa, including specific age ranges and demographics.
Care Setting

Key Highlights

  • HS is a chronic inflammatory skin disorder with significant comorbidities, including metabolic syndrome and depression.

Guideline-Based Recommendations

Diagnosis

    Management

    • First-line therapy includes antibiotics; biologics such as adalimumab and secukinumab may be used for severe cases.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Combination of pharmacological therapies, including antibiotics and biologics, and surgical therapies may be required for disease control.

        Clinical Best Practices

        • Monitor for comorbidities associated with HS, such as obesity, metabolic syndrome, and depression, during treatment.

        Related Resources & Content

        Original Source(s)

        Exploring the Role of the TL1A-DR3 Pathway in Hidradenitis Suppurativa

        • by Juling Sia, Bernett Lee, Hazel H. Oon

        • April 22, 2026

        Related Content

        Top 10 Evidence-Based Essentials in Dermatology

        A structured framework of guidelines, trials, therapies, and tools used in clinical practice

        AI Scribes Lag Clinicians on Note Quality

        A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

        HS Linked to Higher Self-Harm, Suicide Risk

        Prior self-harm episodes and nonviolent methods are more common among HS patients who die by suicide, new research finds.